IQV Stock - IQVIA Holdings Inc.
Unlock GoAI Insights for IQV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B |
| Gross Profit | $5.38B | $5.24B | $5.03B | $4.64B | $3.86B |
| Gross Margin | 34.9% | 35.0% | 34.9% | 33.5% | 34.0% |
| Operating Income | $2.20B | $1.98B | $1.80B | $1.39B | $731.00M |
| Net Income | $1.37B | $1.36B | $1.09B | $966.00M | $279.00M |
| Net Margin | 8.9% | 9.1% | 7.6% | 7.0% | 2.5% |
| EPS | $7.57 | $7.39 | $5.82 | $5.05 | $1.46 |
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Overweight | $265 |
| November 13th 2025 | BMO Capital Markets | Initiation | Outperform | $260 |
| November 3rd 2025 | TD Cowen | Downgrade | Hold | $215 |
| October 29th 2025 | Robert W. Baird | Upgrade | Outperform | $258 |
| October 9th 2025 | HSBC Securities | Upgrade | Buy | $235 |
| September 9th 2025 | Jefferies | Upgrade | Buy | $225 |
| April 25th 2025 | HSBC Securities | Downgrade | Hold | $160 |
| April 10th 2025 | Barclays | Downgrade | Equal Weight | $170 |
| February 3rd 2025 | BTIG Research | Downgrade | Neutral | - |
| December 20th 2024 | Stephens | Initiation | Overweight | $250 |
| October 14th 2024 | Redburn Atlantic | Initiation | Buy | - |
| September 4th 2024 | RBC Capital Mkts | Initiation | Outperform | $275 |
| July 24th 2024 | Jefferies | Downgrade | Hold | $242← $266 |
| June 6th 2024 | Goldman | Initiation | Buy | $270 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $290 |
Earnings History & Surprises
IQVEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $3.40 | — | — | — |
Q4 2025 | Oct 28, 2025 | $2.98 | $3.00 | +0.7% | ✓ BEAT |
Q3 2025 | Jul 22, 2025 | $2.77 | $2.81 | +1.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $2.63 | $2.70 | +2.7% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $3.11 | $3.12 | +0.3% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $2.82 | $2.84 | +0.7% | ✓ BEAT |
Q3 2024 | Jul 22, 2024 | $2.56 | $2.64 | +3.1% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $2.49 | $2.54 | +2.0% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $2.82 | $2.84 | +0.7% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $2.46 | $2.49 | +1.2% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $2.37 | $2.43 | +2.5% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $2.41 | $2.45 | +1.7% | ✓ BEAT |
Q1 2023 | Feb 10, 2023 | $2.75 | $2.78 | +1.1% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $2.39 | $2.48 | +3.8% | ✓ BEAT |
Q3 2022 | Jul 21, 2022 | $2.39 | $2.44 | +2.1% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $2.43 | $2.47 | +1.6% | ✓ BEAT |
Q1 2022 | Feb 15, 2022 | $2.43 | $2.55 | +4.9% | ✓ BEAT |
Q4 2021 | Oct 21, 2021 | $2.13 | $2.17 | +1.9% | ✓ BEAT |
Q3 2021 | Jul 27, 2021 | $2.07 | $2.13 | +2.9% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on IQVIA Hldgs, Raises Price Target to $290
📈 PositiveUBS Maintains Buy on IQVIA Hldgs, Raises Price Target to $280
📈 PositiveMorgan Stanley Maintains Overweight on IQVIA Hldgs, Raises Price Target to $265
📈 PositiveIQV stock has given up its prior loss. IQVIA shares were trading lower after TD Cowen downgraded the stock from Buy to Hold despite raising the price target.
➖ NeutralIQVIA shares are trading lower after TD Cowen downgraded the stock from Buy to Hold despite raising the price target.
➖ NeutralTD Cowen Downgrades IQVIA Hldgs to Hold, Raises Price Target to $215
➖ NeutralCitigroup Maintains Neutral on IQVIA Hldgs, Raises Price Target to $230
➖ NeutralUBS Maintains Buy on IQVIA Hldgs, Raises Price Target to $250
📈 PositiveStifel Maintains Buy on IQVIA Hldgs, Raises Price Target to $254
📈 PositiveTruist Securities Reiterates Buy on IQVIA Hldgs, Raises Price Target to $265
📈 PositiveJP Morgan Maintains Overweight on IQVIA Hldgs, Raises Price Target to $255
📈 PositiveBaird Upgrades IQVIA Hldgs to Outperform, Raises Price Target to $258
📈 PositiveIQVIA Exec Says Co Expects Q4 Revenue To Be In The Range Of $4.2B-$4.3B; Expects Q4 Adjusted Profit To Be $3.35 Per Share
📈 PositiveIQVIA Hldgs Narrows FY2025 Adj EPS Guidance from $11.75-$12.05 to $11.85-$11.95 vs $11.87 Est; Narrows FY2025 Sales Guidance from $16.100B-$16.300B to $16.150B-$16.250B vs $16.170B Est
➖ NeutralIQVIA Hldgs Q3 Adj. EPS $3.00 Beats $2.97 Estimate, Sales $4.100B Beat $4.076B Estimate
📈 PositiveHSBC Upgrades IQVIA Hldgs to Buy, Raises Price Target to $235
📈 PositiveEvercore ISI Group Maintains Outperform on IQVIA Hldgs, Raises Price Target to $240
📈 PositiveJefferies Upgrades IQVIA Hldgs to Buy, Raises Price Target to $225
📈 PositiveIQVIA CFO Ron Bruehlman to retire, Michael Fedock appointed successor
➖ NeutralIQVIA Holdings Names Michael Fedock As CFO Effective February 2026
➖ NeutralFrequently Asked Questions about IQV
What is IQV's current stock price?
What is the analyst price target for IQV?
What sector is IQVIA Holdings Inc. in?
What is IQV's market cap?
Does IQV pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IQV for comparison